This is a retrospective study of patients with ocular surface inflammatory diseases (OSIDs) treated with IKERVIS in a single centre between 2016 to 2019 with at least six months follow-up. Clinical outcome was defined as successful (resolved or stable disease), active disease or drug intolerance. Four hundred and sixty-three patients were included with a mean age of 51.5 years, 59% female and mean follow-up time was 14.6 months. The common diagnosis was dry eye disease (DED) 69.5%, allergic eye disease (AED) 11.4%, and ocular mucous membrane pemphigoid / Steven-Johnson syndrome (OMMP / SJS) 8.2%. Successful treatment was achieved in 74.1% of patients, 9.5% requiring further treatment and 16.4% reporting drug intolerance. The efficacy of IKERVIS was best in DED- 82%, OMMP / SJS- 65.8% and post-keratoplasty- 50%. Drug intolerance was found in significant predictive factors which include: age <70 years, AED and OMMP / SJS groups of patients. AED and post-keratoplasty groups are most likely to require additional treatment comparing DED group. The authors concluded that IKERVIS is useful steroid-sparing agent topical treatment in OSIDs but drugs with better improved drug tolerance are needed in OSIDs patients.
Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases
Reviewed by Jonathan Chan
Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases.
CONTRIBUTOR
Kurt Spiteri Cornish
Sheffield Teaching Hospitals NHS Trust, London, UK.
View Full Profile
